Autism Studies and Related Medical Conditions, January 2009 - TACA

More documents

Recommendations

Info

"OBJECTIVES: In a Pilot Study, the clinical and biochemical effects of thiamine tetrahydrofurfuryl disulfide (TTFD) on autistic spectrum children were investigated. SUBJECTS AND METHODS: Ten children were studied. Diagnosis was confirmed through the use of form E2, a computer assessed symptom score. For practical reasons, TTFD was administered twice daily for two months in the form of rectal suppositories, each containing 50 mg of TTFD. Symptomatic responses were determined through the use of the computer assessed Autism Treatment Evaluation Checklist (ATEC) forms. The erythrocyte transketolase (TKA) and thiamine pyrophosphate effect (TPPE), were measured at outset and on completion of the study to document intracellular thiamine deficiency. Urines from patients were examined at outset, after 30 days and after 60 days of treatment and the concentrations of SH-reactive metals, total protein, sulfate, sulfite, thiosulfate and thiocyanate were determined. The concentrations of metals in hair were also determined. RESULTS: At the beginning of the study thiamine deficiency was observed in 3 out of the 10 patients. Out of 10 patients, 6 had initial urine samples containing arsenic in greater concentration than healthy controls. Traces of mercury were seen in urines from all of these autistic children. Following administration of TTFD an increase in cadmium was seen in 2 children and in lead in one child. Nickel was increased in the urine of one patient during treatment. Sulfur metabolites in urine did not differ from those measured in healthy children. CONCLUSIONS: Thiamine tetrahydrofurfuryl disulfide appears to have a beneficial clinical effect on some autistic children, since 8 of the 10 children improved clinically. We obtained evidence of an association of this increasingly occurring disease with presence of urinary SH-reactive metals, arsenic in particular." 182. Lonsdale presentation to Defeat Autism Now! 2003, Philadelphia http://64.202.182.52/powerpoint/dan2003/Lonsdale.htm 183. A. Holmes, S. Cave, and J.M. El-Dahr. OPEN TRIAL OF CHELATION WITH MES0- 2,3-DIMERCAPTO SUCCINIC ACID (DMSA) AND LIPOIC ACID (LA) IN CHILDREN WITH AUTISM. As submitted to IMFAR, June 2, 2001. "Over 400 patients with autism are currently undergoing treatment for removal of heavy metals. Patients are treated with DMSA alone at doses of 10 mg/kg/dose 3 times a day for 3 days in a row (shorter duration than lead protocol to decrease side effects) with 11 days "off" to allow metals to re-equilibrate. After at least 2 rounds of DMSA alone, the thiol antioxidant lipoic acid (hypothesized to aide in removal of heavy metals across the BBB)is added to each dose of DMSA at 2-3mg/kg/dose. In general, noticeable improvements in language, self-help skills, interaction, and core autistic features are not seen until the patient has been on DMSA with LA for 2-3 months. "Of patients who have been on DMSA/LA for at least 4 months, these results have been noted on general global assessment by parents, teachers, and MDs: age 1-5yrs(n=40): marked improvement 35%, moderate 39%, slight 15%, none 11%; age 6-12yrs Autism Studies & Related Medical Conditions – TACA © Page 350
(n=25): marked 4%, moderate 28%, slight 52%, none 16%; age 13-17 (n=16): moderate 6%, slight 68%, none 26%; age 18+ (n=4): slight 25%, none 75%. For example, a boy 5yr 5mo scored in the average range on a one word expressive vocabulary test 10/00 and at age equivalent 8yr 2mo in 3/01 with no change in education or medication other than starting DMSA/LA. "The majority of children excrete mercury, lead, and other metals, suggesting that there may be a generalized problem with metal metabolism. Side effects include transient increases in hyperactivity, self-stimulatory behavior, and loose stools. Younger children in particular respond well to this therapy with significant improvement in function." 184. DMSA Chelation efficacy PPT presentation by Jane El-Dahr, M.D. 185. Excellent Defeat Autism Now! PPT Presentations online http://www.autism.com/dan/index.htm 186. Lead poisoning treatment--a continuing need (commentary). J Toxicol Clin Toxicol. 2001;39(7):661-3. PMID: 11778663 187. Lightening the lead load in children. Am Fam Physician 2000 62(3):545-54, 559-60 PMID: 10950212 188. Mercury poisoning. Curr Probl Pediatr. 2000 Mar;30(3):91-9. PMID: 10742922 189. Lead poisoning in children. Curr Opin Pediatr. 1997 Apr;9(2):173-7. PMID: 9204246 190. Lead intoxication in children with pervasive developmental disorders. J Toxicol Clin Toxicol. 1996;34(2):177-81. PMID: 8618251 191. Pediatric arsenic ingestion. Am J Emerg Med. 1995 Jul;13(4):432-5. PMID: 7605532 192. Oral chelators for childhood lead poisoning. Pediatr Ann. 1994 23(11):616-9, 623- 6. PMID: 7838614 193. Succimer: the first approved oral lead chelator.Am Fam Physician. 1993 Dec;48(8):1496-502. PMID: 8249780 194. The current role of 2,3-dimercaptosuccinic acid (DMSA) in the management of childhood lead poisoning.Drug Saf. 1993 Aug;9(2):85-92. PMID: 8397892 Autism Studies & Related Medical Conditions – TACA © Page 351
Page 1 and 2:
Autism Studies & Related Medical Co
Page 3 and 4:
Values of free and total carnitine
Page 5 and 6:
observation suggests that certain m
Page 7 and 8:
with autism. These data suggest tha
Page 9 and 10:
Markers rs2056202 and rs2292813 wer
Page 11 and 12:
2- Autism and Gastrointestinal Infl
Page 13 and 14:
than in nondisease controls (p
Page 15 and 16:
Buie, T. M. (2005). "Gastroesophage
Page 17 and 18:
control children and significant nu
Page 19 and 20:
Horvath, K. and J. A. Perman (2002)
Page 21 and 22:
components indicates a role of NFH
Page 23 and 24:
patients with Crohn disease, one of
Page 25 and 26:
analyzed by a registered pediatric
Page 27 and 28:
oligonucleotide probes targeting pr
Page 29 and 30:
would be effective in alleviating c
Page 31 and 32:
demonstrate a focal CD8-dominated g
Page 33 and 34:
Chlamydia pneumoniae and Streptococ
Page 35 and 36:
vaccine (MCV), and once-exposed chi
Page 37 and 38:
Wakefield, A. J., S. H. Murch, et a
Page 39 and 40:
Walker SJ, Hepner K, Segal J, Krigs
Page 41 and 42:
R, Maisawa S, Miki K. Guidelines fo
Page 43 and 44:
approximately 73 and 37kDa in plasm
Page 45 and 46:
Cook, E. H., Jr., B. D. Perry, et a
Page 47 and 48:
evealed, that AAb level may serve a
Page 49 and 50:
findings, which consisted of obstru
Page 51 and 52:
angiography was performed in all fo
Page 53 and 54:
matched non-autistic siblings had d
Page 55 and 56:
Todd, R. D. and R. D. Ciaranello (1
Page 57 and 58:
eaction was further confirmed by DO
Page 59 and 60:
asic protein (MBP) and glial acidic
Page 61 and 62:
exhibit higher than average levels
Page 63 and 64:
Feasby, T., B. Banwell, et al. (200
Page 65 and 66:
each group participated. Observatio
Page 67 and 68:
Rossignol, D. A., L. W. Rossignol,
Page 69 and 70:
Tsuru, T., M. Mori, et al. (2000).
Page 71 and 72:
Anderson, M. P., B. S. Hooker, et a
Page 73 and 74:
continue. The documented prevalence
Page 75 and 76:
contributing factors may contribute
Page 77 and 78:
Chauhan, V., A. Chauhan, et al. (20
Page 79 and 80:
and folate-dependent methionine syn
Page 81 and 82:
confirmed would indicate that autis
Page 83 and 84:
differed significantly in the patie
Page 85 and 86:
end products (AGE's) in autism brai
Page 87 and 88:
cells in area 22 (p
Page 89 and 90:
nutritional, and toxic status in au
Page 91 and 92:
increase in autism in the last deca
Page 93 and 94:
morphological, genetic and animal m
Page 95 and 96:
Rossignol, D. A. (2007). "Hyperbari
Page 97 and 98:
conditions have demonstrated improv
Page 99 and 100:
not been investigated yet, several
Page 101 and 102:
positively correlated in the autist
Page 103 and 104:
abnormalities are present in brain,
Page 105 and 106:
(tetrahydrobiopterin) were selected
Page 107 and 108:
7 - Autism & Infection - 22 citatio
Page 109 and 110:
micro-organisms. The faecal flora o
Page 111 and 112:
Research Support, U.S. Gov't, P.H.S
Page 113 and 114:
presentation of this syndrome among
Page 115 and 116:
disorder. Yamashita Y, Fujimoto C,
Page 117 and 118:
chronic infection may predispose to
Page 119 and 120:
Streptococcus group A. Vojdani A, C
Page 121 and 122:
provides a detailed analysis of a n
Page 123 and 124:
PMID: 16897390 [PubMed - indexed fo
Page 125 and 126:
syndrome and substance abuse, and a
Page 127 and 128:
to contribute to metal-induced neur
Page 129 and 130:
School of Medical Sciences, Tottori
Page 131 and 132:
Review PMID: 16198633 [PubMed - ind
Page 133 and 134:
diseases in humans. Zinc is redox-i
Page 135 and 136:
Office of Vaccines Research and Rev
Page 137 and 138:
Page 139 and 140:
into ferritin or heme. It is not ye
Page 141 and 142:
9 - Dietary Intervention Studies -
Page 143 and 144:
different peptidases resulting in a
Page 145 and 146:
Mechanisms of non-IgE mediated adve
Page 147 and 148:
Reichelt KL, Knivsberg AM.: Can the
Page 149 and 150:
observations is the opioid-excess t
Page 151 and 152:
Patients with gluten ataxia have an
Page 153 and 154:
Hadjivassiliou M, Grunewald RA, Law
Page 155 and 156:
Carroccio A, Montalto G, Custro N,
Page 157 and 158:
Alberti A, Pirrone P, Elia M, Warin
Page 159 and 160:
Thus, a number of milk protein frag
Page 161 and 162:
Abstract: Institute ofPediatrics, L
Page 163 and 164:
Abstract: Service de Psychopatholog
Page 165 and 166:
times peer week) was effective in i
Page 167 and 168:
Reichelt K.L., Knivsberg A.M., Lind
Page 169 and 170:
terminal tetrapeptides into the lef
Page 171 and 172:
Considerable clinical evidence sugg
Page 173 and 174:
material of the P2 fractionation st
Page 175 and 176:
Huebner FR, Lieberman KW, Rubino RP
Page 177 and 178:
Four aspects of clinical evidence f
Page 179 and 180:
Dohan FC: Wheat "consumption" and h
Page 181 and 182:
from 24 children with autism from o
Page 183 and 184:
matched control group. There was a
Page 185 and 186:
administration on certain disorders
Page 187 and 188:
Page 189 and 190:
Coleman M, Steinberg G, Tippett J,
Page 191 and 192:
Dolske MC, Spollen J, McKay S, Lanc
Page 193 and 194:
and myo-inositol (-13%) concentrati
Page 195 and 196:
cobalamin. This was associated with
Page 197 and 198:
(significantly lower ratio of SAM t
Page 199 and 200:
Fifty-three controlled trials of th
Page 201 and 202:
PMID: 6765503 [PubMed - indexed for
Page 203 and 204:
Liebscher DH, Liebscher DE. About t
Page 205 and 206:
from patients were examined at outs
Page 207 and 208:
National College of Naturopathic Me
Page 209 and 210:
OBJECTIVE: Ionic magnesium (Mg(2+))
Page 211 and 212:
Pfeiffer CC, Braverman ER. Zinc, th
Page 213 and 214:
evidence support a role for omega-3
Page 215 and 216:
Page 217 and 218:
scavenge reactive species, then the
Page 219 and 220:
hyperactivity in patients with ADHD
Page 221 and 222:
esponse to folate deprivation. Expr
Page 223 and 224:
improvement may only become apparen
Page 225 and 226:
Walsh WJ, Glab LB, Haakenson ML. Re
Page 227 and 228:
use other internal or external stan
Page 229 and 230:
In contrast, therapy with very high
Page 231 and 232:
increased in affected children comp
Page 233 and 234:
largely unknown, but genetic, envir
Page 235 and 236:
Campbell DB, Sutcliffe JS, Ebert PJ
Page 237 and 238:
OBJECTIVE: Etiologically unexplaine
Page 239 and 240:
globulin and gamma globulins, IgA,
Page 241 and 242:
Fallon J. Could one of the most wid
Page 243 and 244:
Th1-like (IL-2, IFN-gamma) and Th2-
Page 245 and 246:
Jyonouchi H, Geng L, Ruby A, Reddy
Page 247 and 248:
that may be partly associated with
Page 249 and 250:
Department of Neurology, University
Page 251 and 252:
Mehler MF, Kessler JA. Cytokines in
Page 253 and 254:
Niehus R, Lord C. Early medical his
Page 255 and 256:
Pletnikov MV, Jones ML, Rubin SA, M
Page 257 and 258:
Silva SC, Correia C, Fesel C, Barre
Page 259 and 260:
cytokines were measured using speci
Page 261 and 262:
sera) and cerebellum (9% positive s
Page 263 and 264:
Department of Psychiatry, Indiana U
Page 265 and 266:
(DSM)-IV and the International Clas
Page 267 and 268:
Vojdani A, Campbell AW, Anyanwu E,
Page 269 and 270:
Warren RP, Cole P, Odell JD, Pingre
Page 271 and 272:
mechanisms in children with autism.
Page 273 and 274:
12 - Environmental Toxicities (4 ci
Page 275 and 276:
13 - Thimerosal and Toxicity A comp
Page 277 and 278:
Page 279 and 280:
Eye Contact Lens. 2007 Jul;33(4):19
Page 281 and 282:
[Contact allergy to preservatives c
Page 283 and 284:
Marn-Pernat A, Buturović-Ponikvar
Page 285 and 286:
[Thiomersal and immunisations] Weis
Page 287 and 288:
50: The evidence for the safety of
Page 289 and 290:
59: Thimerosal induces DNA breaks,
Page 291 and 292:
68: [Effect of the preservative thi
Page 293 and 294:
Page 295 and 296:
Mutat Res. 1993 May;287(1):29-46. P
Page 297 and 298:
Krug HF, Culig H. Mol Pharmacol. 19
Page 299 and 300: Effect of organic and inorganic mer
Page 301 and 302: Determination of mercury and organo
Page 303 and 304: Cytotoxicity of mercurial preservat
Page 305 and 306: Bourdineaud JP, Bellance N, Bénard
Page 307 and 308: 14: Binstock Citations Controversie
Page 309 and 310: neurodevelopmental delays, which in
Page 311 and 312: 14. Geier DA, Geier MR. A comparati
Page 313 and 314: 29. Boyd Haley, Ph.D. Reduced Level
Page 315 and 316: 40c. Iacono G et al. Intolerance of
Page 317 and 318: affected children compared with bot
Page 319 and 320: "OBJECTIVE: Intestinal pathology, i
Page 321 and 322: 67. Jeff Bradstreet, M.D. A Case-co
Page 323 and 324: in autistic children. In this curre
Page 325 and 326: 87. Semba RD. Vitamin A and immunit
Page 327 and 328: "These results suggest that large o
Page 329 and 330: 94. Bluhm DP, Summers RS. Plasma vi
Page 331 and 332: neonatal gut is different from that
Page 333 and 334: 108. Thony B et al. Tetrahydrobiopt
Page 335 and 336: "Six chemicals, 2-halopropionic aci
Page 337 and 338: immunological functions in diseases
Page 339 and 340: [Note etiologic connection with thi
Page 341 and 342: 149. Magazzu G, Scoglio R. Gastroin
Page 343 and 344: clinical presentations make celiac
Page 345 and 346: 169a. Hadjivassiliou M et al. Does
Page 347 and 348: 174. Headache and CNS white matter
Page 349: histology is difficult to interpret
Page 353 and 354: 199. Stubbs EG et al. Autism and co
Page 355 and 356: 205. Gill HS, Guarner F. Probiotics
Page 357 and 358: patients with IBS. Since the fermen
Page 359 and 360: demonstrate that probiotics possess
Page 361 and 362: 237. James Neubrander, M.D. -- Bioc
Page 363 and 364: significantly more frequent in pati
Page 365 and 366: aseline. Physicians reported qualit
Page 367 and 368: http://www.publichealthreports.org/
Page 369 and 370: No Trade Name Sanofi Pasteur, Ltd 0
Page 371 and 372: Influenza, live FluMist MedImmune V
Page 373 and 374: Calculating Aluminum in Vaccines He
Page 375 and 376: 16 - How Much Money is Spent on Vac
Page 377 and 378: consumer information (promotion mat
Page 379 and 380: evidence to the mercury-vaccine-aut
Page 381 and 382: More from Verstraeten (Now working
Page 383 and 384: 18 -Difference between Number of Va
show all

Autism Studies and Related Medical Conditions, January 2009 - TACA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?